Filing Flows

Filing Flows › Companies › Biomerica › Cash flow

Biomerica cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow−$802K in Q1 FY27 · −$4.0M over twelve months

Operating cash flow−$802K
Free cash flow−$802K
Cash conversion cycle88 days

Analysis

In Q1 FY27, Biomerica generated −$802K of operating cash flow. That is $534K less than in Q1 FY26 (−$268K).

Over the twelve months to Aug 31, 2026, operating cash flow was −$4.0M; the largest uses were operating cash flow ($4.0M); besides operations, cash came from shares issued ($3.2M), other financing ($479K); the cash balance fell by $320K.

Operating cash flow was −$802K against net income of −$1.2M. The largest differences: payables +$216K, stock-based pay +$134K, receivables −$115K.

Its cash conversion cycle was 88 days (receivables 61 + inventory 132 − payables 106).

Free cash flow

Biomerica: free cash flow by quarterBiomerica: free cash flow by quarter−$791KQ2 FY25−$1.0MQ3 FY25−$662KQ4 FY25−$268KQ1 FY26−$991KQ2 FY26−$1.2MQ3 FY26−$912KQ4 FY26−$802KQ1 FY27
Operating cash flow less capital spending.
Biomerica: operating cash flow against capital spendingBiomerica: operating cash flow against capital spendingOperating cash flowCapital spending−$791K$0Q2 FY25−$1.0M$0Q3 FY25−$662K$0Q4 FY25−$268K$0Q1 FY26−$991K$0Q2 FY26−$1.2M$0Q3 FY26−$912K$0Q4 FY26−$802K$0Q1 FY27
Latest (Q1 FY27): Operating cash flow −$802K, Capital spending $0.

Capital allocation, year by year

Biomerica: where the cash came from (up) and went (down), by fiscal yearBiomerica: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY22: Operating cash flow −$479KFY22: Shares issued $2.5MFY22: Capital spending −$57K$2.5MFY22FY23: Operating cash flow −$5.5MFY23: Shares issued $10.1MFY23: Capital spending −$64K$10.1MFY23FY24: Operating cash flow −$5.4MFY24: Capital spending −$51KFY24FY25: Operating cash flow −$3.8MFY25: Shares issued $2.2M$2.2MFY25FY26: Operating cash flow −$3.4MFY26: Shares issued $1.9M$1.9MFY26
Over these 5 years operating cash flow totalled −$18.6M; the largest uses were operating cash flow ($18.6M) and capital spending ($172K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.7M
Debtnone
Net cash$2.7M
Cash runway8 months

Biomerica is burning cash: its operations consume cash, a free cash flow of −$4.0M a year at the current rate against $2.7M of cash and investments: a runway of about 8 months before any new financing.

Where the cash came from and went

Biomerica: sources (+) and uses (−) of cash, Q1 FY27Biomerica: sources (+) and uses (−) of cash, Q1 FY27Shares issued$2.2MCash drawn (+) / kept (−)−$1.4MOperating cash flow−$802KExchange rates−$4K
Biomerica: sources (+) and uses (−) of cash, TTM to Q1 FY27Biomerica: sources (+) and uses (−) of cash, TTM to Q1 FY27Operating cash flow−$4.0MShares issued$3.2MOther financing$479KCash drawn (+) / kept (−)$320KExchange rates−$9KNot reconciled−$1K

From profit to cash

Biomerica: net income to operating cash flow, Q1 FY27Biomerica: net income to operating cash flow, Q1 FY27Net income−$1.2MDepreciation & amortization$15KStock-based pay$134KReceivables−$115KInventory$97KPayables$216KEmployee-related liabilities$60KDeferred revenue−$36KPrepaid and other assets$71KOperating cash flow−$802K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 FY276113210688
Q3 FY268613864160
Q2 FY268111856143
Q1 FY266514365142
Q3 FY2510414161185
Q2 FY258014274148

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q1 FY27−$802K$2.2M−$1.4M−$802K
Q4 FY26−$912K$379K$28K−$912K
Q3 FY26−$1.2M$63K$1.2M−$1.2M
Q2 FY26−$991K$493K$510K−$991K
Q1 FY26−$268K$939K−$654K−$268K
Q4 FY25−$662K−$1K$659K−$662K
Q3 FY25−$1.0M$1.8M−$686K−$1.0M
Q2 FY25−$791K—$448K−$791K

Biomerica: income statement and cash flow

Biomerica, Q1 FY27: revenue $1.3M (-8% year over year), operating margin -97.0%. The chart follows the revenue to costs, profit and cash.

Biomerica: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.